Cantor Fitzgerald raised the firm’s price target on Belite Bio (BLTE) to $266 from $200 and keeps an Overweight rating on the shares. Recent commentary suggested a possibility of a much higher WAC than the $200K/year the firm was modeling, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio price target raised to $201 from $191 at Morgan Stanley
- Belite Bio price target raised to $200 from $195 at BofA
- Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
- Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
- Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win